Sepsis subtypes and differential treatment response to vitamin C: biological sub-study of the LOVIT trial
Authors' conclusion
We report three sepsis subtypes based on inflammatory response profile. No subtype benefitted from vitamin C treatment in the LOVIT trial, with heterogeneity of treatment effect in the magnitude of harm.
Study context
- Population
- LOVIT trial participants with sepsis and plasma samples53.0% of 863 trial participants
- Participants
- 457 participants
- Comparison
- Vitamin C vs placebo, by sepsis subtype
- Vitamin Cn = 233
- Placebon = 224reference
Methodological detailsbiological sub-study, agglomerative hierarchical clustering, analyses blinded to treatment allocation
- Biological sub-study
- Agglomerative hierarchical clustering
- Analyses blinded to treatment allocation
Primary result
As reported in the abstract
Vitamin C treatment effect by sepsis subtype (subgroup)
Vitamin C vs PlaceboOdds ratio (95% CI)
subtype-1
1.04(0.63–1.73)
subtype-2 (highest inflammatory response)
1.33(0.53–3.36)
subtype-3 (lowest inflammatory response)
1.95(0.85–4.49)
Further findings
Anti-inflammatory effect of vitamin C (paired longitudinal samples) · 7 days post-randomisation
- No discernible anti-inflammatory effect of vitamin C; anti-inflammatory effects related to time since randomisation and concomitant hydrocortisone
Original publication
Sepsis subtypes and differential treatment response to vitamin C: biological sub-study of the LOVIT trial. Intensive Care Med. Published 7 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →